Omeros Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OMER research report →
Companywww.omeros.com
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR?
- CEO
- Gregory A. Demopulos
- IPO
- 2009
- Employees
- 202
- HQ
- Seattle, WA, US
Price Chart
Valuation
- Market Cap
- $903.48M
- P/E
- 10.42
- P/S
- 91.32
- P/B
- -14.17
- EV/EBITDA
- -11.62
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -12.39%
- Op Margin
- -1063.86%
- Net Margin
- 871.02%
- ROE
- -54.39%
- ROIC
- -40.60%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-3,350,000 · 97.86%
- EPS
- $-0.05 · 98.05%
- Op Income
- $-122,796,000
- FCF YoY
- 22.02%
Performance & Tape
- 52W High
- $17.65
- 52W Low
- $2.95
- 50D MA
- $12.43
- 200D MA
- $9.45
- Beta
- 2.66
- Avg Volume
- 1.17M
Get TickerSpark's AI analysis on OMER
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 18, 26 | Demopulos Gregory A MD | other | 400,000 |
| Feb 18, 26 | Demopulos Gregory A MD | other | 357,678 |
| Feb 18, 26 | Demopulos Gregory A MD | other | 400,000 |
| Jan 13, 26 | Borges David J. | other | 30,000 |
| Jan 13, 26 | Borges David J. | other | 30,000 |
| Jan 12, 26 | Borges David J. | sell | 30,000 |
| Jan 13, 26 | Borges David J. | sell | 30,000 |
| Oct 13, 25 | Demopulos Gregory A MD | other | 600,000 |
| Oct 13, 25 | Demopulos Gregory A MD | other | 300,000 |
| Jun 30, 25 | Demopulos Gregory A MD | other | 865,000 |
Our OMER Coverage
We haven't published any research on OMER yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OMER Report →